Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bedtime versus morning aspirin for secondary cardiovascular prevention
NL-OMON55498Phase 4Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in cardiac morbidity (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Primary composite cardiovascular outcome. Started Oct 2019; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on NL-OMON55498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55498.